As an unprofitable biotech firm pursuing a Hong Kong IPO under Chapter 18A rules, Yimufeng Biotech finds itself embroiled in a storm of controversy and regulatory scrutiny following a patient death during a clinical trial. The fatal event in the Phase III registered trial of its lead asset IMC002, coupled with the family's allegations regarding risk disclosure, clinical management, and communication failures, has thrust the CAR-T focused innovator into the spotlight just as it refiles its listing application.

The core of this tragedy lies in disputes over trial risk communication, on-site clinical handling, and the interaction between the company and the patient's family. A patient with advanced gastroesophageal junction adenocarcinoma enrolled in the IMC002 Phase III study and passed away from intracranial hemorrhage and brain herniation after receiving the cell infusion. The family contends that the informed consent form only broadly referenced CAR-T related coagulation disorders, failing to explicitly warn about fatal risks such as intracranial bleeding or brain herniation, deeming the disclosure inadequate. They also argue the hospital did not conduct frequent neurological assessments per industry expert consensus, missing a window for early detection. Furthermore, the family states that for six months after the death, Yimufeng never communicated directly with them, with all contact channeled through the hospital. The company only offered a humanitarian compensation package while avoiding any acknowledgment of a causal link between the investigational drug and the fatality.

The hospital and Yimufeng maintain that the cerebral hemorrhage stemmed from a known side effect of lymphodepleting chemotherapy, not the CAR-T product, highlighting a significant divergence in responsibility attribution. Beyond the clinical dispute, the company's external crisis response has revealed management shortcomings. A company director made an emotionally charged, inappropriate remark during a media interview, which was later clarified as a personal statement with a public apology, underscoring lapses in media handling and staff communication controls during the IPO phase.

Under Good Clinical Practice guidelines, sponsors must ensure fully informed consent and establish accessible channels for addressing subject harm. Even if a final investigation concludes the drug did not directly cause the death, the sponsor faces external criticism over the lack of meticulous risk communication and the absence of a direct communication mechanism following a serious adverse event. The definitive conclusion awaits an independent assessment by the hospital's ethics committee and relevant regulatory bodies.

The fatal incident directly pressures Yimufeng's Hong Kong listing timeline. After its initial filing lapsed in February 2026, the company refiled in August to pursue a Chapter 18A listing, with its entire valuation hinging on IMC002, an autologous CAR-T therapy targeting CLDN18.2. The prospectus reveals R&D expenses of RMB 82.2 million in the first half of 2026, with IMC002 clinical costs accounting for a substantial 76.8%. Most other pipeline assets remain in early-stage development, offering little near-term value. The company continues to post significant net losses from 2024 through the first half of 2026, making IPO proceeds critical for advancing its clinical programs.

Notably, the subject passed away in April 2026, months before the August refiling, yet this key adverse event was not specifically highlighted in the updated prospectus. A comparison of the two versions shows the new filing merely removed a phrase from the old one claiming "a favorable safety profile so far" for its candidates, without providing any dedicated disclosure about this death case. The Hong Kong Stock Exchange's Chapter 18A rules explicitly require biotech issuers to fully disclose all significant safety data and material adverse events for core products. Whether this subject fatality constitutes a mandatory disclosure event remains subject to regulatory verification.

IMC002 is among the most advanced CLDN18.2-targeted CAR-T therapies for solid tumors globally, with early clinical data suggesting therapeutic potential. However, this Phase III death has cast a shadow over the product's safety profile. Even if subsequent inquiries exclude a direct causal role for the drug, this incident will likely erode market and investor confidence in the core asset's safety. For a Chapter 18A biotech, clinical trial safety is the lifeline of corporate value. A major controversy can not only delay listing momentum but also directly impair capital market assessments of pipeline worth.

Currently, Yimufeng must await formal conclusions from ethics and regulatory bodies regarding the fatality and appropriately address the family's demands, while simultaneously facing potential queries from the exchange on disclosure adequacy. Clinical trial safety management, information disclosure compliance, and investor confidence—three critical challenges now stand before this IPO-bound biotech firm.